Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies

JAMA Intern Med. 2020 Sep 1;180(9):1145-1146. doi: 10.1001/jamainternmed.2020.2402.

Authors

Mike Z Zhai¹, Carolyn T Lye^{2

3}, Aaron S Kesselheim¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Yale School of Medicine, New Haven, Connecticut.
³ Yale Law School, New Haven, Connecticut.

PMID: 32427277
DOI: 10.1001/jamainternmed.2020.2402

No abstract available

MeSH terms

Access to Information
Antimalarials / pharmacology
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Chloroquine / pharmacology*
Coronavirus Infections* / drug therapy
Coronavirus Infections* / epidemiology
Drug Approval / legislation & jurisprudence*
Drug Repositioning* / methods
Drug Repositioning* / standards
Drug Repositioning* / trends
Evidence-Based Medicine
Humans
Hydroxychloroquine / pharmacology*
Pandemics*
Pneumonia, Viral* / drug therapy
Pneumonia, Viral* / epidemiology
Prior Authorization* / legislation & jurisprudence
Prior Authorization* / trends
SARS-CoV-2

Substances

Antimalarials
Hydroxychloroquine
Chloroquine